MA27735A1 - SUBSTITUTED N-ARYLATED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - Google Patents
SUBSTITUTED N-ARYLATED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTSInfo
- Publication number
- MA27735A1 MA27735A1 MA28430A MA28430A MA27735A1 MA 27735 A1 MA27735 A1 MA 27735A1 MA 28430 A MA28430 A MA 28430A MA 28430 A MA28430 A MA 28430A MA 27735 A1 MA27735 A1 MA 27735A1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- preparation
- heterocycles
- arylated
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
HETEROCYCLES DE N-ARYLE SUBSTITUES, PROCEDE POUR LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS La présente invention concerne des hétérocycles de N-aryle substitués et les sels physiologiquement tolérés et les dérivés physiologiquement fonctionnels de ceux-ci. Composés de formule I dans lesquels les radicaux ont les définitions spécifiées, les N-oxydes et les sels physiologiquement tolérés de ceux-ci et un procédé pour la préparation de ceux-ci sont décrits. Les composés sont adaptés, par exemple, en tant qu'agents anorexigènes.The present invention relates to substituted N-aryl heterocycles and physiologically tolerated salts and physiologically functional derivatives thereof. BACKGROUND OF THE INVENTION The present invention relates to substituted N-aryl heterocycles and physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of formula I wherein the radicals have the specified definitions, N-oxides and physiologically tolerated salts thereof and a process for the preparation thereof are described. The compounds are suitable, for example, as anorectic agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10306250A DE10306250A1 (en) | 2003-02-14 | 2003-02-14 | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27735A1 true MA27735A1 (en) | 2006-02-01 |
Family
ID=32841665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28430A MA27735A1 (en) | 2003-02-14 | 2005-08-11 | SUBSTITUTED N-ARYLATED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1597228A2 (en) |
JP (1) | JP2006517563A (en) |
KR (1) | KR20050101215A (en) |
CN (1) | CN100506792C (en) |
AR (1) | AR044496A1 (en) |
AU (1) | AU2004212145B2 (en) |
BR (1) | BRPI0407504A (en) |
CA (1) | CA2516118A1 (en) |
CO (1) | CO5690548A2 (en) |
DE (1) | DE10306250A1 (en) |
EC (1) | ECSP055967A (en) |
HR (1) | HRP20050710A2 (en) |
MA (1) | MA27735A1 (en) |
MX (1) | MXPA05008449A (en) |
MY (1) | MY139102A (en) |
NO (1) | NO20054220L (en) |
NZ (1) | NZ541823A (en) |
OA (1) | OA13027A (en) |
PA (1) | PA8595901A1 (en) |
PE (1) | PE20040952A1 (en) |
PL (1) | PL378065A1 (en) |
RS (1) | RS20050666A (en) |
RU (1) | RU2005128551A (en) |
TN (1) | TNSN05194A1 (en) |
TW (1) | TW200510297A (en) |
UA (1) | UA86760C2 (en) |
UY (1) | UY28186A1 (en) |
WO (1) | WO2004072025A2 (en) |
ZA (1) | ZA200506369B (en) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
KR20060025141A (en) | 2003-05-15 | 2006-03-20 | 아르퀼 인코포레이티드 | Inhibitors of p38 and methods of using the same |
EP2080757A1 (en) * | 2003-07-24 | 2009-07-22 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
PL1867644T3 (en) * | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
EP2426120A1 (en) | 2003-08-18 | 2012-03-07 | Fujifilm Finechemicals Co., Ltd. | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them |
DE10360745A1 (en) * | 2003-12-23 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New amide compounds having MCH antagonist activity and medicaments containing these compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004003812A1 (en) * | 2004-01-25 | 2005-08-11 | Aventis Pharma Deutschland Gmbh | Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
WO2006022442A1 (en) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
MX2007003321A (en) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents. |
EP1798221A4 (en) * | 2004-10-01 | 2010-04-07 | Banyu Pharma Co Ltd | 2-arylcarboxamide-nitrogeneous heterocycle compound |
EP1805165B1 (en) | 2004-10-18 | 2009-12-16 | Eli Lilly And Company | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mglur3 receptor antagonists |
EP2258704A1 (en) | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
DE102004051277A1 (en) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclic carbonyl compounds |
US8084492B2 (en) * | 2004-11-19 | 2011-12-27 | The New Industry Research Organization | Benzofuran compound and pharmaceutical composition containing the same |
MX2007008134A (en) | 2004-12-30 | 2008-01-16 | Johnson & Johnson | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase. |
EP1846388A4 (en) * | 2005-01-25 | 2011-12-07 | Synta Pharmaceuticals Corp | Thiophene compounds for inflammation and immune-related uses |
BRPI0616646A2 (en) | 2005-09-30 | 2011-06-28 | Hoffmann La Roche | compounds, pharmaceutical composition, use and manufacturing process of selective mch receptor antagonists |
WO2007095124A2 (en) * | 2006-02-10 | 2007-08-23 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
CN101384605A (en) * | 2006-02-15 | 2009-03-11 | 塞诺菲-安万特股份有限公司 | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
TW200800920A (en) * | 2006-02-15 | 2008-01-01 | Sanofi Aventis | Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
EP2009005A4 (en) * | 2006-04-19 | 2010-06-02 | Astellas Pharma Inc | Azolecarboxamide derivative |
LT2010528T (en) | 2006-04-19 | 2017-12-27 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
UA93548C2 (en) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Compounds and compositions as hedgehog pathway modulators |
BRPI0710331A2 (en) | 2006-05-08 | 2012-03-20 | Ariad Pharmaceuticals, Inc | MONOCYCLIC HETEROARYL COMPOUNDS FOR CANCER TREATMENT AND COMPOSITION |
KR20090018104A (en) | 2006-05-08 | 2009-02-19 | 어리어드 파마슈티칼스, 인코포레이티드 | Acetylenic heteroaryl compounds |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
AU2007288245A1 (en) * | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
US20100035914A1 (en) * | 2006-09-11 | 2010-02-11 | Barbara Bertani | Azabicyclic compounds as inhibitors of monoamines reuptake |
WO2008039794A1 (en) * | 2006-09-25 | 2008-04-03 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
AR063311A1 (en) * | 2006-10-18 | 2009-01-21 | Novartis Ag | ORGANIC COMPOUNDS |
US7759344B2 (en) * | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
CN101678019B (en) * | 2007-06-08 | 2016-03-30 | 詹森药业有限公司 | Piperidine/piperazine derivatives |
JP5464709B2 (en) | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Piperidine / piperazine derivatives |
US8835437B2 (en) | 2007-06-08 | 2014-09-16 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine/Piperazine derivatives |
TWI452044B (en) * | 2007-06-15 | 2014-09-11 | Mitsubishi Tanabe Pharma Corp | Morpholine derivative |
TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
TWI445532B (en) | 2007-09-14 | 2014-07-21 | Janssen Pharmaceuticals Inc | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
JP5433579B2 (en) | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-one |
MX2010004003A (en) * | 2007-10-17 | 2010-04-30 | Sanofi Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators. |
BRPI0818581A2 (en) * | 2007-10-17 | 2015-07-21 | Sanofi Aventis | Substituted n-phenyl bipyrrolidine carboxamides and their therapeutic use |
ES2378011T3 (en) * | 2007-10-17 | 2012-04-04 | Sanofi | N-phenyl-bipyrrolidin substituted ureas and therapeutic use thereof |
PL2212282T3 (en) * | 2007-10-17 | 2012-02-29 | Sanofi Sa | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
CA2703106C (en) | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Azolecarboxamide derivatives as trka inhibitors |
ES2637794T3 (en) | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Imidazo [1,2-A] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
EP2070924A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
EP2070925A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
EP2070916A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
RU2364597C1 (en) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM |
EP2296659B1 (en) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
EP2334181A4 (en) * | 2008-09-16 | 2012-03-14 | Merck Sharp & Dohme | Phthalimide derivative metabotropic glutamate r4 ligands |
JP2012006837A (en) * | 2008-09-30 | 2012-01-12 | Mochida Pharmaceut Co Ltd | 2-indoleacrylamide analogue |
ES2466341T3 (en) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8846664B2 (en) | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
AR074466A1 (en) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | PIPERIDINE ESPIRO PIRROLIDINONA AND PIPERIDINONA REPLACED AND ITS THERAPEUTIC USE IN DISEASES MEDIATED BY THE MODULATION OF H3 RECEPTORS. |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
WO2010101246A1 (en) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
WO2010101247A1 (en) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Cyclohexane derivative having npy y5 receptor antagonism |
MX2011011964A (en) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
UA108233C2 (en) | 2010-05-03 | 2015-04-10 | Fatty acid amide hydrolysis activity modulators | |
WO2011143162A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
EP2569304A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
WO2011143150A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
UY33469A (en) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD |
ES2536433T3 (en) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
PL2649069T3 (en) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683702B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012170561A1 (en) * | 2011-06-06 | 2012-12-13 | The Scripps Research Institute (T.S.R.I.) | N-benzylindole modulators of pparg |
WO2012170554A1 (en) | 2011-06-06 | 2012-12-13 | Theodore Mark Kamenecka | N-biphenylmethylindole modulators of pparg |
WO2013078240A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-biphenylmethylbenzimidazole modulators of pparg |
US9102669B2 (en) | 2011-12-06 | 2015-08-11 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors |
WO2013085954A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors |
MX2014013752A (en) * | 2012-05-11 | 2014-12-08 | Abbvie Inc | Nampt inhibitors. |
CA2890002A1 (en) * | 2012-11-05 | 2014-05-08 | Nant Holdings Ip, Llc | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2 |
JP6423372B2 (en) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
UA127921C2 (en) | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
DK3096790T3 (en) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE |
US10016394B2 (en) | 2014-04-16 | 2018-07-10 | The Scripps Research Institute | PPARG modulators for treatment of osteoporosis |
RU2017104856A (en) * | 2014-07-16 | 2018-08-16 | Новоджен Лтд | FUNCTIONALIZED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS |
ES2838573T3 (en) * | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Benzamide derivatives linked as potent ROCK inhibitors |
CA2960274A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Isoxazole carboxamide compounds |
CA2996017A1 (en) * | 2015-08-28 | 2017-03-09 | Glenmark Pharmaceuticals S.A. | Novel carbocyclic compounds as ror gamma modulators |
MA53755A (en) | 2016-03-17 | 2021-08-04 | Hoffmann La Roche | 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE WITH TAAR AGONIST ACTIVITY |
CN108815167B (en) * | 2017-05-24 | 2021-04-13 | 四川晶华生物科技有限公司 | Application of compound in preparing medicine for treating tumor |
TW202136238A (en) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | ROR[gamma]T inhibitor, preparation method therefor and use thereof |
CN115160269A (en) * | 2021-04-02 | 2022-10-11 | 北京大学 | Arylcarboxamide derivatives as positive allosteric modulators of NMDAR |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663336B1 (en) | 1990-06-18 | 1992-09-04 | Adir | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
CA2200433C (en) * | 1994-10-26 | 2006-02-07 | Douglas K. Hutchinson | Phenyloxazolidinone antimicrobials |
KR19990077319A (en) | 1996-01-17 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | Condensed 1,2,4-thiadiazine and condensed 1,4-thiazine derivatives, processes for their preparation and their use |
UA72181C2 (en) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Derivatives of glucanolike peptide-1 |
JP4339402B2 (en) | 1996-12-31 | 2009-10-07 | ドクター・レディーズ・ラボラトリーズ・リミテッド | Novel heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them, and their use in the treatment of diabetes and related diseases |
DE19726167B4 (en) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, process for its preparation and pharmaceutical preparation containing it |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
CO4970713A1 (en) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
WO1999024406A1 (en) * | 1997-11-07 | 1999-05-20 | Schering Corporation | Phenyl-alkyl-imidazoles as h3 receptor antagonists |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (en) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
WO2000035454A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
WO2000047558A1 (en) * | 1999-02-10 | 2000-08-17 | Welfide Corporation | Amide compounds and medicinal use thereof |
CZ20013608A3 (en) * | 1999-04-09 | 2002-05-15 | Astrazeneca Ab | Adamantane derivatives |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
EP1175421A1 (en) | 1999-04-30 | 2002-01-30 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
SE9901875D0 (en) * | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
AU773505B2 (en) | 1999-06-18 | 2004-05-27 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
US6967201B1 (en) | 1999-07-29 | 2005-11-22 | Eli Lilly And Company | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
WO2001016094A1 (en) | 1999-09-01 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
KR100502876B1 (en) | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | Novel Bicyclic Compounds |
ES2252230T3 (en) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | USEFUL TETRAHYDROISOQUINOLINE ANALOGS AS SECRETORS OF GROWTH HORMONE. |
AU6497701A (en) | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
EP1303511A1 (en) * | 2000-07-17 | 2003-04-23 | Ranbaxy Laboratories, Ltd. | Oxazolidinone derivatives as antimicrobials |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
EA200300064A1 (en) * | 2000-07-31 | 2003-06-26 | Смитклайн Бичем Пи-Эл-Си | CARBOXAMIDE CONNECTIONS AND THEIR APPLICATION AS ANTAGONISTS OF HUMAN 11CBY RECEPTOR |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Polyarylcarboxamides useful as lipid lowering agents |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Biphenylcarboxamides useful as lipid lowering agents |
JP2002338537A (en) * | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | Amide compound and its medicinal use |
WO2002098839A1 (en) * | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides and process for preparation thereof |
WO2002098871A1 (en) * | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Phenylcarboxamides and process for preparation thereof |
AU2002346048A1 (en) * | 2001-06-07 | 2002-12-16 | Merck And Co., Inc. | Benzodiazepine bradykinin antagonists |
DE10142734A1 (en) | 2001-08-31 | 2003-03-27 | Aventis Pharma Gmbh | New (((oxazolylalkyl)-cycloalkyl)-alkyl)-benzoic acid derivatives, are peroxisome proliferator activated receptor agonists or antagonists used e.g. for treating lipid metabolism disorders, type II diabetes, syndrome X and obesity |
US7662826B2 (en) * | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
JP2004175739A (en) * | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | Medicinal composition |
-
2003
- 2003-02-14 DE DE10306250A patent/DE10306250A1/en not_active Withdrawn
-
2004
- 2004-02-13 WO PCT/EP2004/001342 patent/WO2004072025A2/en active Search and Examination
- 2004-02-13 CA CA002516118A patent/CA2516118A1/en not_active Abandoned
- 2004-02-13 AU AU2004212145A patent/AU2004212145B2/en not_active Ceased
- 2004-02-13 RU RU2005128551/04A patent/RU2005128551A/en not_active Application Discontinuation
- 2004-02-13 PA PA20048595901A patent/PA8595901A1/en unknown
- 2004-02-13 MY MYPI20040479A patent/MY139102A/en unknown
- 2004-02-13 JP JP2006501827A patent/JP2006517563A/en active Pending
- 2004-02-13 PL PL378065A patent/PL378065A1/en not_active Application Discontinuation
- 2004-02-13 BR BRPI0407504-8A patent/BRPI0407504A/en not_active IP Right Cessation
- 2004-02-13 UY UY28186A patent/UY28186A1/en unknown
- 2004-02-13 OA OA1200500227A patent/OA13027A/en unknown
- 2004-02-13 PE PE2004000158A patent/PE20040952A1/en not_active Application Discontinuation
- 2004-02-13 RS YUP-2005/0666A patent/RS20050666A/en unknown
- 2004-02-13 MX MXPA05008449A patent/MXPA05008449A/en active IP Right Grant
- 2004-02-13 KR KR1020057014989A patent/KR20050101215A/en not_active Application Discontinuation
- 2004-02-13 NZ NZ541823A patent/NZ541823A/en unknown
- 2004-02-13 UA UAA200508733A patent/UA86760C2/en unknown
- 2004-02-13 EP EP04710808A patent/EP1597228A2/en not_active Withdrawn
- 2004-02-13 TW TW093103412A patent/TW200510297A/en unknown
- 2004-02-13 CN CNB2004800098606A patent/CN100506792C/en not_active Expired - Fee Related
- 2004-02-16 AR ARP040100469A patent/AR044496A1/en unknown
-
2005
- 2005-08-10 ZA ZA200506369A patent/ZA200506369B/en unknown
- 2005-08-11 EC EC2005005967A patent/ECSP055967A/en unknown
- 2005-08-11 MA MA28430A patent/MA27735A1/en unknown
- 2005-08-11 CO CO05079788A patent/CO5690548A2/en not_active Application Discontinuation
- 2005-08-12 HR HR20050710A patent/HRP20050710A2/en not_active Application Discontinuation
- 2005-08-12 TN TNP2005000194A patent/TNSN05194A1/en unknown
- 2005-09-12 NO NO20054220A patent/NO20054220L/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN100506792C (en) | 2009-07-01 |
EP1597228A2 (en) | 2005-11-23 |
RU2005128551A (en) | 2006-02-10 |
NO20054220D0 (en) | 2005-09-12 |
KR20050101215A (en) | 2005-10-20 |
AR044496A1 (en) | 2005-09-14 |
PL378065A1 (en) | 2006-02-20 |
NZ541823A (en) | 2009-01-31 |
BRPI0407504A (en) | 2006-02-14 |
HRP20050710A2 (en) | 2006-07-31 |
WO2004072025A2 (en) | 2004-08-26 |
AU2004212145B2 (en) | 2010-06-17 |
TW200510297A (en) | 2005-03-16 |
AU2004212145A1 (en) | 2004-08-26 |
PA8595901A1 (en) | 2004-09-16 |
MXPA05008449A (en) | 2006-05-25 |
JP2006517563A (en) | 2006-07-27 |
CA2516118A1 (en) | 2004-08-26 |
NO20054220L (en) | 2005-10-28 |
UY28186A1 (en) | 2004-09-30 |
ZA200506369B (en) | 2006-07-26 |
ECSP055967A (en) | 2006-01-16 |
OA13027A (en) | 2006-11-10 |
WO2004072025A3 (en) | 2004-12-23 |
RS20050666A (en) | 2007-12-31 |
PE20040952A1 (en) | 2005-02-08 |
MY139102A (en) | 2009-08-28 |
DE10306250A1 (en) | 2004-09-09 |
UA86760C2 (en) | 2009-05-25 |
CO5690548A2 (en) | 2006-10-31 |
TNSN05194A1 (en) | 2007-06-11 |
CN1774418A (en) | 2006-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27735A1 (en) | SUBSTITUTED N-ARYLATED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
MA27654A1 (en) | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-a] -4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | |
MA28747B1 (en) | Pyridine Derivatives | |
MA27774A1 (en) | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | |
MA27734A1 (en) | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO [1,2-a] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | |
MA29926B1 (en) | PYRAZINE DERIVATIVES | |
MA30403B1 (en) | CYCLOALKYLAMINE ACID DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | |
TNSN05073A1 (en) | NOVEL SPIROCONDENSE QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
MA30696B1 (en) | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL) -ACETIC DERIVATIVES | |
MA27990A1 (en) | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | |
MA31894B1 (en) | Organic compositions | |
MA43639B1 (en) | New ammonium derivatives, process for their preparation and pharmaceutical compositions containing them | |
MA31419B1 (en) | PYRIDINE DERIVATIVES | |
MA27560A1 (en) | NOVEL HETEROCYCLIC FLUORGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE | |
MA27559A1 (en) | NOVEL AROMATIC FLUORGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE | |
MA30911B1 (en) | NOVEL SULFONAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS | |
MA26727A1 (en) | NOVEL PYRIMIDINE DERIVATIVES OF SORBITOL DEHYDROGENASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
MA29772B1 (en) | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | |
MA27568A1 (en) | PYRROLOPYRIMIDINE DERIVATIVES | |
MA26952A1 (en) | IMIDAZOLE DERIVATIVES WITH CONDENSED ARYLATED OR HETEROARYL CORES, USEFUL AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. | |
MA28007A1 (en) | ORGANIC COMPOUNDS | |
MA27775A1 (en) | ORGANIC COMPOUNDS | |
MA30916B1 (en) | NOVEL BENZAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS | |
MA26696A1 (en) | NOVEL TETRAHYDROBENZAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
TNSN07167A1 (en) | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |